Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 21 results.
User Information
Export Records
  1. 1.   How do I… facilitate a rapid response to a public health emergency requiring plasma collection with a public-private partnership?
  2. Miller, Maureen J; Skrzekut, Adam; Kracalik, Ian; Jones, Jefferson M; Lofy, Kathryn H; Konkle, Barbara A; Haley, N Rebecca; Duvenhage, Michael; Bonnett, Tyler; Holbrook, Michael; Higgs, Elizabeth; Basavaraju, Sridhar V; Paranjape, Suman
  3. Transfusion. 2021, Sep 12; 61(10):
  1. 2.   Subchronic and Chronic Toxicity Evaluation of Inorganic Nanoparticles for Delivery Applications
  2. Mohammadpour, Raziye; Dobrovolskaia,Marina; Cheney, Darwin L; Greish, Khaled F; Ghandehari, Hamidreza
  3. Advanced drug delivery reviews. 2019, Jul 08; 144(SI): 112-132.
  1. 3.   Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
  2. Kawaguchi, Kei; Miyake, Kentaro; Han, Qinghong; Li, Shukuan; Tan, Yuying; Igarashi, Kentaro; Kiyuna, Tasuku; Miyake, Masuyo; Higuchi, Takashi; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Wangsiricharoen, Sintawat; Bouvet, Michael; Singh, Shree Ram; Unno, Michiaki; Hoffman, Robert M
  3. Cancer Letters. 2018, Jun 18; 432: 251-259.
  1. 4.   Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection
  2. Houser, K. V.; Gretebeck, L.; Ying, T.; Wang, Y.; Vogel, L.; Lamirande, E. W.; Bock, K. W.; Moore, I. N.; Dimitrov, D. S.; Subbarao, K.
  3. The Journal of infectious diseases. 2016, 15-May; 213(10): 1557-61.
  1. 5.   Systemic flaws cannot be fixed with minor tweaks
  2. Cuss, S. M.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2014, 1-Jul; 111(26): E2635.
  1. 6.   Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis
  2. Bode, C.; Kinjo, T.; Alvord, W. G.; Klinman, D. M.
  3. Carcinogenesis. 2014, May; 35(5): 1078-83.
  1. 7.   Evaluation of a library outreach program to research labs
  2. Brandenburg, M. D.; Doss, A.; Frederick, T. E.
  3. Medical reference services quarterly. 2010, Jul; 29(3): 249-59.
  1. 8.   Targeting prostate cancer stem cells
  2. Crea, F.; Mathews, L. A.; Farrar, W. L.; Hurt, E. M.
  3. Anti-cancer agents in medicinal chemistry. 2009, Dec; 9(10): 1105-13.
  1. 9.   Energy dispersive X-ray analysis of titanium dioxide nanoparticle distribution after intravenous and subcutaneous injection in mice
  2. Patri, A.; Umbreit, T.; Zheng, J.; Nagashima, K.; Goering, P.; Francke-Carroll, S.; Gordon, E.; Weaver, J.; Miller, T.; Sadrieh, N.; McNeil, S.; Stratmeyer, M.
  3. Journal of applied toxicology : JAT. 2009, Nov; 29(8): 662-72.
  1. 10.   Virus maturation as a new HIV-1 therapeutic target
  2. Adamson, C. S.; Salzwedel, K.; Freed, E. O.
  3. Expert opinion on therapeutic targets. 2009, Aug; 13(8): 895-908.
  1. 11.   Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
  2. Adamson, C. S.; Freed, E. O.
  3. Molecular Interventions. 2009, Apr; 9(2): 70-4.
  1. 12.   Engineered CH2 domains (nanoantibodies)
  2. Dimitrov, D. S.
  3. Mabs. 2009, Jan-Feb; 1(1): 26-8.
  1. 13.   Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
  2. Gardner, E. R.; Smith, N. F.; Figg, W. D.; Sparreboom, A.
  3. Journal of experimental & clinical cancer research : CR. 2009 28: 99.
  1. 14.   Soft alkyl ether prodrugs of a model phenolic drug: the effect of incorporation of ethyleneoxy groups on transdermal delivery
  2. Thomas, J. D.; Majumdar, S.; Sloan, K. B.
  3. Molecules (Basel, Switzerland). 2009 14(10): 4231-45.
  1. 15.   Individualizing cancer care with interoperable information systems
  2. McCormick, K. A.
  3. Studies in Health Technology and Informatics. 2009 146: 383-390.
  1. 16.   Use of mutant SIV DNA immunization to mimic attenuated virus vaccines
  2. Arthur, L. O.; Gorelick, R. J.; Benveniste, R. E.; Lifson, J. D.; Yovandich, J. L.; Rossio, J. L.; Esser, M. T.; Bess, J. W.; Henderson, L. E.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 74 (abstract no. 40)-74 (abstract no. 40).
  1. 17.   Conditioned immune response to interferon-gamma in humans
  2. Longo, D. L.; Duffey, P. L.; Kopp, W. C.; Heyes, M. P.; Alvord, W. G.; Sharfman, W. H.; Schmidt, P. J.; Rubinow, D. R.; Rosenstein, D. L.
  3. Clinical Immunology. 1999 90(2): 173-181.
  1. 18.   SIV nucleocapsid mutant DNA vaccine: immunization and challenge
  2. Arthur, L.; Benveniste, R.; Lifson, J.; Yovandich, J.; Rossio, J.; Bess, J.; Henderson, L.; Gorelick, R.
  3. Conference on Retroviruses and Opportunistic Infections. 1998, 81 (abstract no. 4002)-81 (abstract no. 4002).
  1. 19.   Immunization of macaques with full-length SIV nucleocapsid mutant DNA
  2. Gorelick, R.; Benveniste, R.; Lifson, J.; Rossio, J.; Bess, J.; Henderson, L.; Arthur, L. O.
  3. Conference on Advances in AIDS Vaccine Development. 1997, 73.
  1. 20.   Gestation stage- and carcinogen-specific K-ras mutations in mouse lung tumors initiated transplacentally
  2. Sithanandam, G.; Diwan, B. A.; Anderson, L. M.
  3. Annual Meeting of the American Association for Cancer Research. 1997, 38 A1896.
  1. 21.   Synergistic interactions between UCN-01 and various anticancer agents in vitro: Relationship to p53 function
  2. Monks, A.; Vaigro-Wolff, A.; Hose, C.; Sausville, E. A.; O'Connor, P. M.
  3. Annual Meeting of the American Association for Cancer Research. 1997, 38 A2157.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel